Despite comprehensive evaluation including heart biopsy, approximately half of patients with initially unexplained heart failure are labeled as having idiopathic cardiomyopathy. 1 The high prevalence of these poorly understood cardiomyopathies has led to ongoing interest about a potential role for viral infection leading to heart failure.
Multiple cardiotropic viruses have been implicated in the development of myocarditis, dilated cardiomyopathy and isolated left ventricular diastolic dysfunction. [2] [3] [4] The enteroviruses (most commonly coxsackievirus) were the first to be described, followed by adenovirus, and more recently the human erythrovirus known as parvovirus B19.
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Given the variable detection rates, the clinical significance of viral recovery from heart tissue remains controversial, with some studies claiming viruses are a ubiquitous cause of cardiomyopathy [7] [8] [9] [10] [11] [12] and others arguing that these same viruses may be a normal, nonpathologic element of the host microbiome. [13] [14] [15] The prevalence of viral recovery in patients presenting for a heart failure evaluation remains uncertain, as does the interaction between cardiotropic viral persistence and clinical phenotype as defined by presenting symptoms, cardiac imaging and histopathology. To date, the majority of studies on have been performed in Europe.
We set out to prospectively determine the prevalence of cardiotropic viruses and their associated clinicopathological profiles in adult heart failure patients in the United States undergoing endomyocardial biopsy (EMB).
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Methods

Patient Population
Subjects were prospectively enrolled at Brigham and Women's Hospital (Boston, were adult males or non-pregnant females (age >18yrs) undergoing diagnostic endomyocardial biopsy as part of evaluation for new onset cardiomyopathy or refractory heart failure. 16 Patients were ineligible for participation if they had an uncorrected coagulopathy (INR>1.3), platelet count <75,000/mm 3 , right ventricular systolic pressure >60mmHg, body mass index (BMI) >40 kg/m 2 , or significant thoracic deformity, which could increase biopsy risk.
Baseline demographic and clinical data was collected including age, sex, selfidentified race, BMI, duration of heart failure symptoms, and presence of viral prodrome.
Patients were further characterized according to their dominant clinical feature, which could include one or more of the following: congestive heart failure, ventricular arrhythmia, or chest pain syndrome. Physical examination at enrollment included assessment of resting heart rate, blood pressure, and the presence of an S3 gallop.
Patients underwent right heart catheterization using a balloon-tipped, flow-directed catheter. Cardiac output was determined by the Fick method. Coronary angiography was also performed in patients with a history suggestive of ischemic heart disease or with at least two coronary risk factors. Surface echocardiography was performed in all patients demographic and clinical data was collected including age, s BMI, duration of heart failure symptoms, and presence of vir end of the study period, ten patients underwent off-protocol cardiac MRI with gadolinium contrast during their index hospital stay. A final clinicopathological diagnosis was assigned as previously described. 17 Patients with an acute presentation with positive biomarkers and MRI with late-gadolinium enhancement and T2 signal consistent with edema could receive a diagnosis of myocarditis even in the absence of cellular infiltrate on biopsy.
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Endomyocardial biopsy
Biopsy of the right ventricular septum was performed via the right internal jugular vein with the use of a disposable bioptome. Each histologic specimen was stained with hematoxylin-eosin and examined at a minimum of 4 levels. The median number of biopsies taken per patient was 5 (range 3-8). Special stains, such as Congo red for amyloid or Prussian blue for iron deposition, were performed when appropriate.
Histopathologic analysis allowed classification of formalin-fixed biopsies for evidence of myocarditis according to the Dallas criteria. 19 Biopsies were reviewed by two pathologists blinded to both the clinical scenario and results of molecular testing. Each biopsy was scored for myocyte hypertrophy (0-3), perivascular and interstitial fibrosis (0-3), evidence of chronic ischemic injury (sub-endocardial myocyte vacuolization, 0-3) or infarction, along with other findings such as non-cellular infiltration.
In all, there were 110 eligible study subjects who provided informed consent but seven did not complete EMB and three subjects had insufficient sample for viral testing.
Of the seven patients not biopsied, three had significant coronary disease on angiography, obviating the need for biopsy to uncover heart failure etiology; one developed transient d via the right i i i i i i int n n n n n n t speci ci ci ci i ci cime me me me me me men n n n n n n wa wa wa wa wa wa was s s s s s s st s s m e s a sin and examined at a minimum of 4 levels. The median num er patient was 5 (range 3-8). Special stains, such as Congo r sian blue for iron deposition, were performed when appropria complete heart block during right heart catheterization requiring temporary pacemaker; one subject had a right ventricular perforation leading to a small, hemodynamically insignificant pericardial effusion and cessation of further biopsy attempts; one had significant pulmonary hypertension secondary to pulmonary fibrosis precluding biopsy;
and one had a recovery in ejection fraction on ventriculography. The remaining 100 subjects participated in the primary analysis. To serve as controls without heart failure, endomyocardial tissue samples were obtained from four autopsied hearts from patients whose causes of death was deemed to be non-cardiac. 
Viral Recovery
Parvovirus Viral Load Detection
Parvovirus B19 copy number and the amount of endogenous myocardial DNA were determined by a multiplex assay in single reactions using oligonucleotides and TaqMan probes detecting all three parvovirus B19 genotypes (1, 2, and 3), consisting of Older age was associated with recovery of parvovirus B19 genotype 2 with positivity in the two oldest patients in this series (age 55 and 61 years), consistent with its presence in subjects born before 1973. 15 Baseline history, physical examination, echocardiography and hemodynamic assessment are reported in Table 1 . Overall this is a middle aged (mean age 50 years) cohort of heart failure patients with mainly subacute or chronic disease (median symptom duration 5 months, IQR 1-13 months). Most patients had systolic dysfunction (median EF 30%, IQR 20-45%), though one-third of subjects biopsied had a preserved ejection fraction. There were few aggregate differences between subjects with and without A final clinicopathological diagnosis was assigned to each subject, integrating features of the clinical presentation, cardiac imaging and heart biopsy. 17 (Table 2) Idiopathic cardiomyopathy, either dilated or non-dilated, was the most common clinicopathologic diagnosis of patients with both parvovirus B19-positive (75%) and parvovirus B19-negative biopsies (56%). There was no difference in the prevalence of 
Clinical Profiles of Parvovirus B19 in Heart Failure
Patient specific data about clinical presentation, echocardiography, histopathology, and viral genotype for parvovirus B19 positive subjects are summarized in Table 3 . There was marked heterogeneity in clinical presentation among those patients with parvovirus B19. Parvovirus B19-positive subjects with heart failure ranged in age from 21 to 61 years old and were from multiple different ethnic groups (10 Caucasian, 1
Hispanic, 1 African-American).
Cases with parvovirus B19 presented with both recent onset heart failure (<2 weeks) and with chronic, refractory congestive symptoms (nearly 6 years). Subjects with parvovirus B19 had both preserved (4 of 12) and reduced ejection fractions (8 of 12).
The degree of left-ventricular remodeling as assessed by end-diastolic dimension was poorly correlated with the duration of symptoms. There was a varying degree of myocyte hypertrophy and fibrosis, with more severe changes consistent with an element of chronic injury found in patients with greater remodeling, as measured by a larger left ventricular end-diastolic dimension and longer symptom duration. None of the 12 subjects with parvovirus B19 amplified by PCR met Dallas criteria for active or borderline myocarditis, despite two subjects having late gadolinium enhancement on cardiac MRI.
Brief clinical vignettes for each parvovirus B19 positive subject are included in the Supplemental Table to further Germany evaluated left atrial tissue in patients undergoing cardiac surgery and found that 85% had evidence of parvovirus B19 by nested PCR. 25 In marked contrast, no subject in the present study had more than one cardiotropic virus isolated and the only virus recovered was parvovirus B19 in only 12% of patients.
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Several explanations could account for variable recovery rates in heart failure patients. Both Kuhl report and the present study enrolled patients with a similar mean ejection fraction and duration of symptoms. 9 However, the former only reported patients with idiopathic LV dysfunction, excluding those with alternative heart failure etiologies, such as ischemic cardiomyopathy. Even if we restrict our cohort to those patients with idiopathic heart failure, only 14% had parvovirus recovery. Another explanation is the lack of standardization in PCR assays and amplification thresholds. Our study only included PCR on a single biopsy sample, whereas other studies have used between 4-6 biopsy samples. Increased sampling has the potential to increase the frequency of genuine viral recovery along with the number of different viruses identified in a given patient. Repeated sampling and multiple PCR cycles, however, could contribute to an increase the aggregate false positive rate. In a follow-up series of patients undergoing serial EMB with PCR, 22% of subjects who were initially parvovirus B19 positive had subsequently negative biopsies (4 samples amplified), which is unexpected given the biology of viral persistence.
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The seropositive rate of parvovirus B19 IgG in children under 15 years is 30-50%
and increases to >90% in the elderly. 26 Given the high background seropositive prevalence worldwide, it is unlikely that infection rates of parvovirus in the United States tive heart failur ur ur ur ur ur ure hort t to to to to to to o th th th th th th hos os os os os os ose e e e e e e pa pa p p p p p t 
Parvovirus Infection and Cardiac Persistence
Viral persistence may represent a state after acute infection and prior to immunologic clearance. Viral persistence has been postulated to be one marker of failure to respond to immunotherapy for idiopathic cardiomyopathy. 27, 28 Persistence as defined by recovery of virus on serial biopsies has also been associated with deteriorating ejection fraction. 10 Data from several recent reports have demonstrated parvovirus B19 persistence in asymptomatic individuals without myocarditis or dilated cardiomyopathy. 13, 14, 25 In our case series, sequencing of parvovirus B19 isolated revealed the two oldest subjects (aged 55 and 61 years) had recovery of genotype 2.
Since parvovirus genotype 2 has not been in circulation since at least 1973, this is consistent with life-long myocardial persistence rather than acute infection. 15 These data suggest that if cardiac tissue is a lifelong reservoir for parvovirus B19, then detection by PCR alone may be insufficient to declare a pathologic effect. Parvovirus was recovered from EMB in patients with a wide variety of putative heart failure etiologies and clinical presentations in this study. Patients had both a preserved ejection fraction (33%) and reduced systolic function (67%). Interestingly, the single subject presenting with acute heart symptoms (<2 weeks) had an ischemic cardiomyopathy that improved with revascularization, yet tested positive for parvovirus on biopsy. The ischemic burden in this patient was recognized only after biopsy had already been performed and revascularization improved cardiac function. Parvovirus has been previously linked to endothelial dysfunction, which may lead to myocardial injury or a presentation mimicking acute myocardial infarction. 7, 29, 30 However, in the current study, parvovirus was not associated with ischemic fibrosis or sub-endocardial vacuolization on histopathology, both markers of chronic ischemic injury.
Clinical Heterogeneity and Viral
Parvovirus has previously been recovered from both postmortem and antemortem biopsies in adult and pediatric patients with myocarditis. 31, 32 In the present case series, the frequency of myocarditis defined by cellular infiltrate or cardiac MRI and appropriate clinical syndrome was no different between parvovirus positive and negative subjects.
These data confirm the absence of correlation between Dallas criteria infiltrate. 9, 33 Thus, parvovirus B19 recovery alone cannot be claimed to represent the cause of chronic myocarditis. Yet, two parvovirus-positive subjects displayed clinical evidence of myopericarditis with recurrent chest pain, troponin elevation, normal coronary angiography, and a cardiac MRI consistent with myocarditis. This presentation has been described as "parvomyocarditis" and has been shown to mimic acute myocardial infarction. us has previously been recovered from both postmortem and and pediatric patients with myocarditis. 31, 32 In the present c
Although we hypothesized that the two subjects with presumed parvomyocarditis would harbor higher myocardial parvovirus B19 loads than the subjects who were unexpectedly found to be positive for parvovirus B19,, the highest parvovirus copy numbers were found in patients with idiopathic cardiomyopathy. In turn, the two patients with presumed parvomyocarditis had similar viral loads as autopsy controls without heart disease. These viral loads, however, are consistent with those previously reported in patients with both systolic and diastolic dysfunction. 7, 11 While we cannot comment on the variation of viral load over time, or the effect of patient age on copy number, these data further argue against a primary pathogenic role for parvovirus B19 in adults with heart failure. More extensive interpretation of these findings is impossible given the limited sample size but may be a target for future studies.
Several small case series have suggested that interferon ß-1b may be useful as a treatment for subjects with dilated cardiomyopathy in whom viral genome is detected on EMB. 28, 34 However, a more recent, longer term follow-up trial (36 months) could not confirm the promising results from pilot studies and showed no significant clinical benefit conferred by interferon therapy in HF patients. Of interest, the lack of therapeutic effect in this recent trial was postulated to be due to the presence of parvovirus B19 in many of the virus-positive subjects 35 . While antiviral therapy may be of benefit for parvovirus B19-associated myocarditis in children 24 in whom primary (acute) infection is more common 25 , our results support recent studies 35 and argue against the use of antiviral therapy in adult HF patients with parvovirus persistence. ize but may be a target for future studies.
Study Limitations
small case series have suggested that interferon ß-1b may be d bjects with dilated cardiomyopathy in whom viral genome is PCR has been subject to assay variability, which we attempted to minimize by performing assays in a certified diagnostic laboratory. There may be selection bias in who was referred for EMB at our center, though the indications for EMB conformed to published indications. 16 Since this data is derived from a single biopsy sample, we are unable to comment on natural history of parvovirus B19 positive patients or its prognostic importance. The sensitivity of viral detection may be low in a single biopsy rather than several. The background prevalence of parvovirus B19 is unknown for this cohort since assays were only obtained on parvovirus B19 positive subjects to confirm chronic rather than acute infection. Since viral loads were determined from samples remaining after primary PCR analyses, not all samples contained sufficient DNA for multiplex qPCR amplification. Although the mere presence of parvovirus B19 genome in myocardium was not found to be clinically significant, a possible role through mRNA or protein production cannot be excluded. Since our PCR assays cannot provide localization of viral elements, it is unclear whether the microvasculature or cardiac myocytes themselves are harboring parvovirus, which could provide further insight into a potential pathomechanism.
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Conclusions
Parvovirus B19 was the only virus recovered using PCR of biopsies from adult heart failure patients with new or unexplained cardiomyopathy in this prospective, singlecenter study in the United States. These data confirm that parvovirus may persist lifelong in the myocardium after acute infection, as has been described for other human tissues. was not found to be clinically significant, a possible role thro ction cannot be excluded. Since our PCR assays cannot prov recovery and no association with myocardial inflammation. Our studies do not suggest a causative role for parvovirus persistence in HF and advocate against the use of antiviral therapy in these patients.
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